Endothelin-1 potentiates human smooth muscle cell growth to PDGF: Effects of ET(A) and ET(B) receptor blockade

Circulation

Volumn 100, Issue 1, 1999, Pages 5-8

  Yang, Zhihong ^b   Krasnici, Nazmi ^b   Lüscher, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

Cells; Growth substances; Kinases; Platelet derived factors

Indexed keywords

BOSENTAN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; DARUSENTAN; ENDOTHELIN 1; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RETINOBLASTOMA PROTEIN; THYMIDINE; TRITIUM;

AORTA MEDIA; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOGENESIS; MUSCLE GROWTH; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

EID: 0033529389     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.1.5     Document Type: Article

References (14)

1. Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M. Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol Sci. 1998: 19:5-8.
2. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994;89:1203-1208.
3. Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett. 1988;238:249-252.
4. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis. 1989;78:225-228.
5. Scott-Burden T, Resink TJ, Hahn AW, Vanhoutte PM. Induction of endothelin secretion by angiotensin II: effects on growth and synthetic activity of vascular smooth muscle cells. J Cardiovasc Pharmacol. 1991; 17(suppl 7):S96-S100.
6. Jahan H, Kobayashi S, Nishimura J, Kanaide H. Endothelin-1 and angiotensin II act as progression but not competence growth factors in vascular smooth muscle cells. Eur J Pharmacol. 1996;295:261-269.
7. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
8. Blenis J. Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci U S A. 1993;90:5889-5892.
9. Morgan DO. Principles of CDK regulation. Nature. 1995;374:131-134.
10. Yang Z, Oemar BS, Carrel T, Kipfer B, Julmy F. Lüscher TF. Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: role of PDGF receptors, mitogen-activated protein kinase, and cyclin-dependent kinase inhibitors. Circulation. 1998;97: 181-187.
11. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-330.
12. McKenna CJ, Burke SE, Opgenorth TJ, Padley RJ, Camrud LJ, Camrud AR, Johnson J, Carlson PJ, Lerman A, Holmes DR Jr, Schwartz RS. Selective ET(A) receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model. Circulation. 1998;97:2551-2556.
13. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325:997-1001.
14. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein coupled receptors. Nature. 1996; 379:557-560.